Multiple TIGIT clinical data readouts anticipated throughout 2025, including >400 patients from two Phase 2 trials and one Phase 1/2 ...

Neuberg Diagnostics, a Chennai-based diagnostics chain, has secured Rs 940 crore from Kotak Alt, becoming the largest ever ...

Founder and Managing Director GSK Velu expressed enthusiasm about the milestone, stating it aligns with the company's vision ...

Kotak Strategic Situations India Fund II invests ₹940 crore in Neuberg Diagnostics for expansion and IPO preparation.

Kotak Strategic Situations India Fund II, managed by Kotak Alternate Asset Managers Limited (Kotak Alt), has announced an ...

Ouro Medicines, a biotechnology company developing immune reset therapeutics for people living with chronic immune-mediated diseases, today announced its launch with $120 million in funding. The ...

The round is one of Europe’s largest-ever biotech VC deals, signalling investor appetite for the booming weight loss market.

Ouro is planning to leverage T cell engagers to deplete B cells and “reset” the immune system to treat immune-mediated ...

T cell engagers are having a moment, much like antibody-drug conjugates have for the past two years. The cell-depleting ...

Armed with $115 million and a clinical-stage asset, another player is emerging in the increasingly crowded T cell engager ...

Find insight on Zydus Lifesciences, Biotech and more in the latest Market Talks covering the Health Care sector.

Shingrix in 2017 received US FDA approval to prevent shingles in adults aged 50 and older. Since 2021, it has been approved for use in immunocompromised patients aged 18 and up. GSK estimates around ...